{
 "built_et": "2026-10-20 ~4:10 PM ET",
 "subject": "Hulscher N, Thorp JA, Victory K, Gillooly P, McCullough PA, Risch H. Combination ivermectin and mebendazole: a comprehensive review ... Zenodo preprint, Oct 19, 2026. doi:10.5281/zenodo.23475387",
 "review_admissions": {
  "narrative_review_no_prisma": true,
  "combination_preclinical_studies": 0,
  "coi": "all authors affiliated with and/or salaried by The Wellness Company",
  "review_mentions_twc_sells_product": false
 },
 "crossref_scan": {
  "references": 151,
  "with_doi": 138,
  "resolved": 137,
  "unresolved": [
   "10.22038/apjmt.2026.89341.1521 (ref 18)"
  ],
  "retracted_cited_works": {
   "36": {
    "doi": "10.1002/prp2.954",
    "title": "RETRACTED: Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways",
    "retraction_disclosed_in_review": true
   },
   "72": {
    "doi": "10.1042/BSR20192489",
    "title": "Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells",
    "retraction_disclosed_in_review": false
   },
   "127": {
    "doi": "10.3389/fphar.2019.00681",
    "title": "A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma)",
    "retraction_disclosed_in_review": false
   },
   "133": {
    "doi": "10.21873/anticanres.18194",
    "title": "RETRACTED: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort",
    "retraction_disclosed_in_review": true
   }
  },
  "expression_of_concern_cited_works": {
   "50": {
    "doi": "10.1038/s41523-021-00229-5",
    "notice": "10.1038/s41523-026-00988-z (June 5, 2026); correction 10.1038/s41523-026-00908-1 (Feb 27, 2026)",
    "disclosed_in_review": false
   }
  },
  "method": "Crossref REST API works/{doi} and works?filter=updates:{doi}, Oct 20, 2026"
 },
 "clinical_efficacy_studies": [
  {
   "study": "Hegazy 2022, Tanta University, Egypt",
   "drug": "mebendazole",
   "design": "randomized, 40 people (paper: double-blind placebo)",
   "review_class": "positive",
   "status_oct20": "no notice; registry lists no masking, active comparator, 6-month response outcome, still recruiting, completion Dec 2028",
   "doi": "10.1016/j.lfs.2022.120536"
  },
  {
   "study": "METRICS (Agrawal 2019)",
   "drug": "mebendazole + metformin, atorvastatin, doxycycline",
   "design": "single-arm, 95 people vs historical comparators",
   "review_class": "positive",
   "status_oct20": "RETRACTED Oct 13, 2026 (MHRA: trial without appropriate ethics approval or informed consent; data inaccuracies). Review calls it an unresolved 2023 expression of concern. Registry NCT02201381: withdrawn, 0 enrolled",
   "doi": "10.3389/fphar.2019.00681"
  },
  {
   "study": "Hulscher 2026 (TWC customers)",
   "drug": "ivermectin 25 mg + mebendazole 250 mg capsules",
   "design": "survey cohort, 197 people, 122 followed, self-reported, no control",
   "review_class": "positive",
   "status_oct20": "RETRACTED Oct 1, 2026 (methods could not support the 84.4% benefit claim; no misconduct alleged). Review discloses it and disputes it",
   "doi": "10.21873/anticanres.18194"
  },
  {
   "study": "Patil 2022, Tata Memorial, India",
   "drug": "mebendazole + lomustine or temozolomide",
   "design": "randomized open-label phase 2, 88 people, mebendazole in both arms",
   "review_class": "neutral",
   "status_oct20": "missed its 55% 9-month survival bar (36.6% and 45%)",
   "doi": "10.1016/j.eclinm.2022.101449"
  },
  {
   "study": "Mansoori 2021, Uppsala (Repos Pharma)",
   "drug": "mebendazole up to 4 g/day",
   "design": "single-arm phase 2a, 11 people",
   "review_class": "neutral",
   "status_oct20": "every treated patient progressed by 8 weeks; 4 met hyperprogression criteria; 5 reached target level",
   "doi": "10.1038/s41598-021-88433-y"
  },
  {
   "study": "Yuan 2025, Cedars-Sinai (NCT05318469)",
   "drug": "ivermectin + balstilimab or pembrolizumab",
   "design": "single-arm phase 1/2, interim",
   "review_class": "interim",
   "status_oct20": "interim abstract: median PFS 2.5 months, 4-month clinical benefit 37.5%; still recruiting",
   "doi": "10.1200/JCO.2025.43.16_suppl.e13146"
  }
 ],
 "hegazy_registry": {
  "masking": "NONE",
  "arms": [
   "ACTIVE_COMPARATOR",
   "EXPERIMENTAL"
  ],
  "primary_outcome": "number of patients with tumour response / 6 months",
  "status": "RECRUITING",
  "primary_completion": "2028-12",
  "enrollment": {
   "count": 40,
   "type": "ESTIMATED"
  },
  "start": "2019-04-01",
  "first_submitted": "2019-04-22"
 },
 "benchmarks": {
  "NO16966_first_line_bev_oxaliplatin_PFS_months": 9.4,
  "E3200_previously_treated_FOLFOX4_bev": {
   "PFS_months": 7.3,
   "ORR_pct": 22.7
  },
  "E3200_bev_alone": {
   "PFS_months": 2.7,
   "ORR_pct": 3.3
  },
  "hegazy_control_FOLFOX4_bev_placebo": {
   "PFS_months": 3.0,
   "ORR_pct": 10
  },
  "hegazy_mebendazole_arm": {
   "PFS_months": 9.25,
   "ORR_pct": 65
  }
 },
 "concentrations": {
  "ivermectin_lab_uM": 5.0,
  "ivermectin_lab_ng_ml": 4376.0,
  "ivermectin_12mg_cmax_ng_ml": 46.6,
  "ivermectin_12mg_cmax_uM": 0.053,
  "gap_12mg_x": 94,
  "ivermectin_25mg_est_uM_if_proportional": 0.111,
  "gap_25mg_x": 45,
  "ivermectin_120mg_est_uM_if_proportional": 0.53,
  "gap_120mg_x": 9.4,
  "ivermectin_120mg_fed_est_uM_label_2_5x_food": 1.33,
  "gap_120mg_fed_x": 3.8,
  "mebendazole_label_max_ng_ml": 30,
  "mebendazole_label_max_uM": 0.1,
  "mebendazole_lab_ic50_uM_glioma_panel": [
   0.11,
   0.31
  ],
  "mebendazole_target_300ng_ml_uM": 1.02,
  "mebendazole_target_reached": "5 of 11 (Mansoori 2021)",
  "mebendazole_hydatid_10mgkg_range_ng_ml": [
   17.5,
   500
  ]
 },
 "ctgov": {
  "ivermectin_anticancer": [
   {
    "nct": "NCT07487805",
    "title": "Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)",
    "status": "NOT_YET_RECRUITING",
    "enroll": 80,
    "start": "2026-12",
    "has_results": false,
    "sponsor": "University of Florida"
   },
   {
    "nct": "NCT05318469",
    "title": "Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer",
    "status": "RECRUITING",
    "enroll": 34,
    "start": "2023-10-13",
    "has_results": false,
    "sponsor": "Yuan Yuan"
   }
  ],
  "mebendazole_anticancer": [
   {
    "nct": "NCT01837862",
    "title": "A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas",
    "status": "ACTIVE_NOT_RECRUITING",
    "enroll": 10,
    "start": "2013-10-22",
    "has_results": false,
    "sponsor": "Julie Krystal"
   },
   {
    "nct": "NCT02201381",
    "title": "Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer",
    "status": "WITHDRAWN",
    "enroll": 0,
    "start": "2022-05-23",
    "has_results": false,
    "sponsor": "Health Clinics Limited"
   },
   {
    "nct": "NCT03628079",
    "title": "A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.",
    "status": "TERMINATED",
    "enroll": 11,
    "start": "2018-05-25",
    "has_results": false,
    "sponsor": "Repos Pharma"
   },
   {
    "nct": "NCT02644291",
    "title": "Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors",
    "status": "COMPLETED",
    "enroll": 16,
    "start": "2016-05",
    "has_results": false,
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
   },
   {
    "nct": "NCT03925662",
    "title": "Mebendazole as Adjuvant Treatment for Colon Cancer",
    "status": "RECRUITING",
    "enroll": 40,
    "start": "2019-04-01",
    "has_results": false,
    "sponsor": "Sherief Abd-Elsalam"
   },
   {
    "nct": "NCT01729260",
    "title": "Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide",
    "status": "COMPLETED",
    "enroll": 24,
    "start": "2013-04-04",
    "has_results": false,
    "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
   },
   {
    "nct": "NCT04443049",
    "title": "To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.",
    "status": "UNKNOWN",
    "enroll": 170,
    "start": "2020-07-10",
    "has_results": false,
    "sponsor": "Institute of Liver and Biliary Sciences, India"
   }
  ],
  "excluded": {
   "NCT04447235": "ivermectin + losartan for COVID-19 in cancer patients (not an anticancer test)",
   "NCT07396714": "warts",
   "NCT02366884": "private clinic \"atavistic chemotherapy\" (anti-bacterial, anti-fungal, anti-protozoal classes), status unknown since 2022, no results",
   "others": "drug not an intervention (supportive, imaging, other agents)"
  },
  "both_drugs_together": 0
 },
 "twc_product": {
  "url": "https://www.twc.health/products/ivermectin-mebendazole",
  "capsule": "25 mg ivermectin + 250 mg mebendazole",
  "prices_usd": {
   "90ct": "599.99",
   "45ct": "349.99"
  },
  "store_created_at": "2025-01-31T18:36:26-05:00",
  "label_schedule": "21 days on, 21 days off, 4 cycles",
  "cancer_study_page": {
   "url": "https://www.twc.health/pages/ivermectin-mebendazole-cancer-study",
   "checked_et": "4:05 PM ET Oct 20, 2026",
   "quotes": [
    "Retracted by the journal. Click here to find out why",
    "Peer reviewed. Published. Then retracted. No errors were found. The data didn't change.",
    "Order now & talk to a provider",
    "Ivermectin + Mebendazole An important tool in the battle against cancer."
   ]
  },
  "claims_vs_record": {
   "twc_page": "Passed a rigorous three-month review.",
   "journal_dates": "Received April 8, 2026; revision received April 20, 2026; accepted April 24, 2026 (16 days)",
   "paper_limitations": "Given these threats to validity, therapeutic benefit cannot be inferred.",
   "twc_page_no_errors": "No errors were found.",
   "retraction_notice": "methodological and analytical problems undermine the reliability of its central clinical-benefit conclusions"
  },
  "product_page_marketed_as": "Parasite Cleanse; \"Doctor's available to consult for off-label use\""
 },
 "x": {
  "checked_et": "2026-10-20 ~3:55-4:05 PM ET (X API recent counts, UTC days)",
  "ivm_mbz_fbz_cancer_en_noRT": {
   "query": "(ivermectin OR mebendazole OR fenbendazole) cancer lang:en -is:retweet",
   "days": {
    "2026-10-14": 1415,
    "2026-10-15": 1483,
    "2026-10-16": 1040,
    "2026-10-17": 1176,
    "2026-10-18": 1066,
    "2026-10-19": 1010,
    "2026-10-20_to_19:54UTC": 881
   },
   "total": 8071
  },
  "same_original_posts_excl_cancer_survivor_spam": {
   "query": "(ivermectin OR mebendazole OR fenbendazole) cancer lang:en -is:retweet -is:reply -\"cancer survivor\"",
   "days": {
    "2026-10-14": 222,
    "2026-10-15": 182,
    "2026-10-16": 234,
    "2026-10-17": 211,
    "2026-10-18": 161,
    "2026-10-19": 165,
    "2026-10-20_to_19:54UTC": 148
   },
   "total": 1323
  },
  "ivermectin_mebendazole_en_noRT": {
   "query": "ivermectin mebendazole lang:en -is:retweet",
   "days": {
    "2026-10-14": 238,
    "2026-10-15": 587,
    "2026-10-16": 238,
    "2026-10-17": 283,
    "2026-10-18": 135,
    "2026-10-19": 129,
    "2026-10-20_to_20:02UTC": 308
   },
   "total": 1918
  },
  "tiktok_peptide_en_noRT": {
   "query": "tiktok (peptide OR peptides OR bpc OR retatrutide) lang:en -is:retweet",
   "days": {
    "2026-10-14": 6,
    "2026-10-15": 4,
    "2026-10-16": 9,
    "2026-10-17": 7,
    "2026-10-18": 12,
    "2026-10-19": 10,
    "2026-10-20_to_19:54UTC": 54
   }
  },
  "posts": {
   "hulscher_review_post": {
    "id": "2112532337451782188",
    "url": "https://x.com/NicHulscher/status/2112532337451782188",
    "created_utc": "2026-10-20T13:12:12Z",
    "created_et": "Oct 20, 9:12 AM ET",
    "author_followers": 312142,
    "impressions": 86807,
    "likes": 6228,
    "reposts": 2473,
    "bookmarks": 3841,
    "replies": 104,
    "quotes": 85,
    "checked_et": "Oct 20 ~4:02 PM ET"
   },
   "hulscher_teaser_post": {
    "id": "2112158895317696634",
    "created_utc": "2026-10-19T12:28:17Z",
    "created_et": "Oct 19, 8:28 AM ET",
    "text": "Within 48 hours, the FULL POWER of ivermectin and mebendazole for cancer will be revealed.",
    "impressions": 398429,
    "likes": 24727,
    "reposts": 5225,
    "bookmarks": 4231
   },
   "twc_post": {
    "id": "2112579889878692260",
    "url": "https://x.com/twc_health/status/2112579889878692260",
    "author": "The Wellness Company @twc_health, 70,008 followers",
    "impressions": 1057
   },
   "mercer_counter_article": {
    "id": "2112607831212052617",
    "url": "https://x.com/amindlesswasted/status/2112607831212052617",
    "title": "37 Cancer Mechanisms, Two Retractions, and One Missing Clinical Trial",
    "impressions": 152
   }
  },
  "trending_story": {
   "id": "2112552619117891920",
   "url": "https://x.com/i/trending/2112552619117891920",
   "name": "Review Highlights Anticancer Potential of Ivermectin and Mebendazole Combo",
   "updated_utc": "2026-10-20T17:33:30Z"
  }
 }
}